Azurin-p28
Also known as: AZU‑p28, Azurin‑derived peptide, Azurin‑derived peptide p28, Azurin‑p28, NSC745104, p28, p28-azurin
Source Azurin-p28 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Azurin‑p28 (p28) is a 28‑amino‑acid peptide derived from the bacterial protein azurin. It has been investigated as a tumor‑penetrating, p53‑stabilizing anticancer agent in early‑phase clinical studies but has not received regulatory approval.
Mechanism of Action
Derived from bacterial azurin, p28 binds to and stabilizes tumor suppressor p53, enhancing its transcriptional activity and promoting apoptosis of cancer cells; also interferes with angiogenic signaling.
Routes of Administration
Goals & Uses
- Cancer therapyOncologyModerate
- Solid tumor treatmentOncologyModerate
- Glioblastoma adjunct therapyOncologyLow
- Pediatric CNS tumor treatmentOncologyModerate
- Anti-angiogenesisOncology / VascularLow
- Solid tumor therapy (breast, melanoma, liver)OncologyModerate
- Glioblastoma multiforme treatmentOncologyModerate
- p53 pathway restorationMolecular TargetModerate
Contraindications
- Known hypersensitivity to azurin-p28 or bacterial-derived peptidesAllergy/immunologyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Known hypersensitivity to azurin or related bacterial proteinsAllergyModerate
- Tumors with mutant/null p53MolecularModerate
- Known hypersensitivity to azurin‑derived peptidesAllergyModerate
Adverse Effects
- HeadacheNeurologicUncommonPain in the head or upper neck
- Elevated liver enzymes (transaminitis)HepaticUncommon
- Infusion‑related reactionsGeneralCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- FatigueGeneralUncommonLow energy or tiredness
- Infusion-related reactionsHypersensitivityUncommon
- Infusion‑related reactionGeneralCommon
Drug Interactions
- MDM2 inhibitors (e.g., nutlin-3, RG7112)Low
- Cytotoxic chemotherapy (general)Low
- Concurrent chemotherapy agentsModerate
- CYP450 substratesLow
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
- Pediatric patients (<3 years)PediatricRelative
Regulatory Status
- European UnionUnknownNo EU marketing authorization as of 2026
- United StatesInvestigationalInvestigational New Drug (IND) status; orphan drug designation for glioblastoma
- United KingdomUnknownNo MHRA approval or designation confirmed
Orphan drug designation granted in the United States for certain solid tumors; no approved indication as of 2026.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Azurin-p28?
Azurin‑p28 (p28) is a 28‑amino‑acid peptide derived from the bacterial protein azurin. It has been investigated as a tumor‑penetrating, p53‑stabilizing anticancer agent in early‑phase clinical studies but has not received regulatory approval.
What is Azurin-p28 used for?
Azurin-p28 is educationally associated with: Cancer therapy, Solid tumor treatment, Glioblastoma adjunct therapy, Pediatric CNS tumor treatment, Anti-angiogenesis, Solid tumor therapy (breast, melanoma, liver), Glioblastoma multiforme treatment, p53 pathway restoration. Educational only — not medical advice.
How is Azurin-p28 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Azurin-p28?
Reported adverse effects include: Headache, Elevated liver enzymes (transaminitis), Infusion‑related reactions, Nausea, Fatigue, Infusion-related reactions, Infusion‑related reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Azurin-p28?
Recorded contraindications: Known hypersensitivity to azurin-p28 or bacterial-derived peptides, Pregnancy, Known hypersensitivity to azurin or related bacterial proteins, Tumors with mutant/null p53, Known hypersensitivity to azurin‑derived peptides. Consult a qualified clinician before use.